Literature DB >> 16445832

Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan.

Tetsuya Mori1, Tetsuya Takimoto, Naoyuki Katano, Akira Kikuchi, Ken Tabuchi, Ryoji Kobayashi, Hiroshi Ayukawa, Masa-aki Kumagai, Keizo Horibe, Masahito Tsurusawa.   

Abstract

This report presents a retrospective study of 26 Japanese children with recurrent anaplastic large cell lymphoma. The first relapses were documented at a median of 10.5 months after the initial diagnosis. Twenty-four patients achieved a second remission. After a median follow-up period of 47 months, 18 patients are still alive: 15 patients are in second complete remission (CR), three patients are in third CR or later. The 5 year overall and relapse-free survival rates were 61 +/- 12% and 51 +/- 12% respectively. The patients who received allogeneic haematopoietic stem cell transplantation during second CR showed a superior outcome to other patients.

Entities:  

Mesh:

Year:  2006        PMID: 16445832     DOI: 10.1111/j.1365-2141.2005.05910.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  10 in total

1.  Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning for a child with recurrent anaplastic large cell lymphoma.

Authors:  Hideaki Ohta; Shigenori Kusuki; Hisao Yoshida; Emiko Sato; Yoshiko Hashii; Keiichi Ozono
Journal:  Int J Hematol       Date:  2010-06-15       Impact factor: 2.490

Review 2.  Stem cell transplantation in childhood non-Hodgkin's lymphomas.

Authors:  Fatma V Okur; Robert Krance
Journal:  Curr Hematol Malig Rep       Date:  2010-10       Impact factor: 3.952

Review 3.  Advances in hematopoietic stem cell transplantation in childhood and adolescent lymphomas.

Authors:  Mitchell S Cairo; Willi Woessmann; John Pagel
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-13       Impact factor: 5.742

4.  Allogeneic hematopoietic stem cell transplant for relapsed and refractory non-Hodgkin lymphoma in pediatric patients.

Authors:  Swati Naik; Caridad A Martinez; Bilal Omer; Ghadir Sasa; Khaled Yassine; Carl E Allen; Kala Kamdar; Robert Orth; Mengfen Wu; Kathryn Leung; Stephen Gottschalk; Malcolm K Brenner; Helen E Heslop; Robert A Krance
Journal:  Blood Adv       Date:  2019-09-24

5.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037

6.  Phase II trial of CH5424802 (alectinib hydrochloride) for recurrent or refractory ALK-positive anaplastic large cell lymphoma: study protocol for a non-randomized non-controlled trial.

Authors:  Hirokazu Nagai; Reiji Fukano; Masahiro Sekimizu; Akiko Kada; Akiko M Saito; Ryuta Asada; Tetsuya Mori
Journal:  Nagoya J Med Sci       Date:  2017-08       Impact factor: 1.131

7.  Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.

Authors:  Masahiro Sekimizu; Akihiro Iguchi; Tetsuya Mori; Yuhki Koga; Akiko Kada; Akiko M Saito; Keizo Horibe
Journal:  BMC Cancer       Date:  2018-02-01       Impact factor: 4.430

Review 8.  Immune Response against ALK in Children with ALK-Positive Anaplastic Large Cell Lymphoma.

Authors:  Serena Stadler; Vijay Kumar Singh; Fabian Knörr; Christine Damm-Welk; Wilhelm Woessmann
Journal:  Cancers (Basel)       Date:  2018-04-10       Impact factor: 6.639

Review 9.  Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond.

Authors:  Nina Prokoph; Hugo Larose; Megan S Lim; G A Amos Burke; Suzanne D Turner
Journal:  Cancers (Basel)       Date:  2018-03-30       Impact factor: 6.639

10.  Alectinib for relapsed or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: An open-label phase II trial.

Authors:  Reiji Fukano; Tetsuya Mori; Masahiro Sekimizu; Ilseung Choi; Akiko Kada; Akiko Moriya Saito; Ryuta Asada; Kengo Takeuchi; Takashi Terauchi; Ukihide Tateishi; Keizo Horibe; Hirokazu Nagai
Journal:  Cancer Sci       Date:  2020-10-28       Impact factor: 6.716

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.